Lhasa Limited shared knowledge shared progress
Loading...

Publications

Jump to results
Authors
Publication Type
Publication Year
Related Products
Reset
New search
TitlePublishedTypeProducts
Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA)April 2021
Data Sharing Projects using Vitic [an infographic]April 2021pdf fileExcipientsIntermediatesVitic Nexus
Enhancing carbon acid pKa prediction by augmentation of sparse experimental datasets with accurate AIBL (QM) derived valuesMarch 2021Zeneth
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk - SOT 2021 Presentation SlidesMarch 2021pdf fileKaptisDerek Nexus
Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and postmarketing reportsMarch 2021
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk - PETA Science Consortium Webinar SlidesMarch 2021pdf fileKaptis
The eTRANSAFE Project on Translational Safety Assessment through Integrative Knowledge Management: Achievements and PerspectivesMarch 2021
Case study on the use of integrated approaches to testing and assessment for the prediction of a 90-day repeated dose toxicity study (OECD 408) for 2-Ethylbutyric acid using a read-across approach from other branched carboxylic acids.March 2021
Guidelines for FAIR sharing of preclinical safety and off-target pharmacology dataMarch 2021
2021 Webinar - An overview of Effiris 2.1; An enhanced qualitative model suite for anticipating and mitigating adverse drug reactions – Slides and recordingFebruary 2021pdf fileEffiris
Bringing Together Scientific Disciplines for Collaborative Undertakings: A Vision for Advancing the Adverse Outcome Pathway FrameworkFebruary 2021pdf fileKaptis
Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosaminesFebruary 2021
Deriving compound-specific exposure limits for chemicals used in pharmaceutical synthesis: Challenges in expert decision-making exemplified through a case study-based workshopFebruary 2021
Beyond adverse outcome pathways: making toxicity predictions from event networks, SAR models, data and knowledgeJanuary 2021Kaptis
Nexus ICH M7 Expert Review Support Functionality (an infographic)December 2020pdf fileDerek NexusSarah Nexus
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic RiskDecember 2020pdf fileKaptis
HuskinDB, a database for skin permeation of xenobioticsDecember 2020
2020 AI/PDE Webinar -Acceptable Intake (AI) and Permitted Daily Exposure (PDE) data sharing project for pharmaceutical impurities - SlidesDecember 2020pdf file
2020 AI/PDE Webinar -Acceptable Intake (AI) and Permitted Daily Exposure (PDE) data sharing project for pharmaceutical impurities - RecordingDecember 2020
Application of adverse outcome pathways (AOPs) to support genotoxicity assessmentNovember 2020pdf fileKaptis
2020 Zeneth 8 webinar - Zeneth 8: A re-designed and improved forced degradation prediction system for organic compounds - RecordingNovember 2020Zeneth
2020 Zeneth 8 webinar - Zeneth 8: A re-designed and improved forced degradation prediction system for organic compounds - SlidesNovember 2020pdf fileZeneth
Aromatic Amines Database 2020.1.0 Release NotesNovember 2020pdf file
Setaria 3.3 Installation GuideNovember 2020pdf fileSetaria
Setaria 3.3 Release NotesNovember 2020pdf fileSetaria

© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.